Sector: Healthcare | Industry: Advanced Medical Equipment & Technology |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 5301 Stevens Creek Blvd SANTA CLARA CA 95051 |
Tel: | N/A |
Website: | https://www.agilent.com |
IR: | See website |
Key People | ||
Michael R. Mcmullen President, Chief Executive Officer, Director | Robert W. Mcmahon Chief Financial Officer, Senior Vice President | Michael Tang Senior Vice President, General Counsel, Secretary |
Dominique P. Grau Senior Vice President - Human Resources and Global Communications | Henrik Ancher-Jensen Senior Vice President - Agilent, President - Order Fulfillment and Supply Chain | Philip Binns Senior Vice President, Agilent and President of Life Sciences and Applied Markets Group |
Padraig Mcdonnell Senior Vice President, President of Agilent CrossLab | Rodney Gonsalves Chief Accounting Officer, Vice President, Corporate Controllership |
Business Overview |
Agilent Technologies, Inc. is engaged in providing application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. It operates in the life sciences, diagnostics and applied chemical markets. Its life sciences and applied markets segment provides application-focused solutions that include instruments, consumables and software that enable customers to identify, quantify and analyze the physical and biological properties of substances and products. Its diagnostics and genomics segment includes the genomics, nucleic acid contract manufacturing and research and development, pathology, companion diagnostics, reagent partnership and biomolecular analysis businesses. The Agilent CrossLab segment offers services portfolio, which includes repairs, parts, maintenance, installations, training, compliance support, software as a service, asset management, consulting and various other custom services to support the laboratory operations. |
Financial Overview |
For the three months ended 31 January 2024, Agilent Technologies Inc revenues decreased 6% to $1.66B. Net income decreased 1% to $348M. Revenues reflect Life Sciences and Applied Markets segment decrease of 18% to $846M, United States segment decrease of 8% to $630M, Asia Pacific segment decrease of 7% to $570M. Net income also reflects Life Sciences and Applied Markets segment income decrease of 25% to $236M. |
Employees: | 17,700 as of Jan 31, 2024 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $43,449M as of Jan 31, 2024 |
Annual revenue (TTM): | $6,735M as of Jan 31, 2024 |
EBITDA (TTM): | $1,918M as of Jan 31, 2024 |
Net annual income (TTM): | $1,236M as of Jan 31, 2024 |
Free cash flow (TTM): | $1,382M as of Jan 31, 2024 |
Net Debt Last Fiscal Year: | $807.00M as of Jan 31, 2024 |
Shares outstanding: | 293,055,284 as of Feb 27, 2024 |
Index Membership: | S&P 500 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |